Author(s): Vilas Sonagre, Piyush Lulay, Meka Lingam, Srinivas Arutla, Sachi Patel, Meghana Kulkarni


DOI: Not Available

Address: Vilas Sonagre1*, Piyush Lulay2, Meka Lingam3, Srinivas Arutla3, Sachi Patel3 and Meghana Kulkarni4
1Sharad Pawar College of Pharmacy Wanadongri, Hingna Road, Nagpur-441110,
2Vels College of Pharmacy, Pallavaram, Chennai 600117,
3Dr. Reddy’s Laboratories, Hyderabad 500016,
4SVKM's NMIMS University, Mumbai 400056.
Corresponding author

Published In:   Volume - 5,      Issue - 1,     Year - 2012

Since the identification of gastro erosive reflux disease and peptic ulcer in the early 1900’s, the line of treatment of the disease has evolved reasonably. The antisecretory agents used in the treatment regime have developed, beginning with the introduction of cimetidine in the mid-1970s to proton pump inhibitor (PPI) omeprazole in 1989 and subsequently dexlansoprazole dual delayed release in 2009. This development was done to address the unmet needs of patients suffering from severe esophagitis and nocturnal acid breakthrough (NAB). The available PPI formulations which had short plasma elimination half life of less than 2 hours could not inhibit the proton pumps synthesized in the nighttime hours. The inadequacy in symptom control and high prevalence of NAB in patients with more severe gastro esophageal disease still prevailed after medication. This was identified as the unmet needs of PPI formulations. Although novel formulations, including immediate release omeprazole may offer some advantages over existing formulations, it does not address many of the potential unmet needs of patients with these disorders. However, these needs are addressed by dual delayed release technology which delivers dose in a pulsatile manner and provides acid suppression for prolonged period of time.

Cite this article:
Vilas Sonagre, Piyush Lulay, Meka Lingam, Srinivas Arutla, Sachi Patel, Meghana Kulkarni. Current Advances in Technology of Proton Pump Inhibitor Formulations. Research J. Pharm. and Tech. 5(1): Jan. 2012; Page 20-26,

Vilas Sonagre, Piyush Lulay, Meka Lingam, Srinivas Arutla, Sachi Patel, Meghana Kulkarni. Current Advances in Technology of Proton Pump Inhibitor Formulations. Research J. Pharm. and Tech. 5(1): Jan. 2012; Page 20-26,   Available on:


1.       Dent J. Review article: from 1906 to 2006- a century of major evolution of understanding of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006; 24: 1269-81

2.       Tanimura, al. Prevalence of gastro-oesophageal reflux disease in patients who attended the emergency room. Nippon Shokakibyo Gakki Zasshi. 2008; 105, 54-59

3.       Kahrilas P.J, Shaheen N.J, Vaezi M.F, American Gastroenterological Association Institute, Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on management of gastrooesophageal reflux disease. Gastroenterology. 2008; 135(4): 1392-1413

4.       Mainie I, Tutuian R, Shay S. et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006; 55(10): 1398-1402

5.       Vakil N, Van Zanten S.V, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of Gastro-esophageal Reflux Disease (GERD) – a global evidence based consensus. Am J Gastroenterol. 2006; 101: 1900-20

6.       Katz P.O, Scheiman J.M, Barkun A.N. Review article: acid-related disease – what are the unmet clinical needs? Aliment Pharmacol Ther. 2006; 23: 9–22

7.       Heresey S.J, Sachs G, Gastric acid secretion. Physiol Rev. 1995; 75: 155-89

8.       Fass R. Nocturnal Acid Breakthrough: A Critical Assessment. Hospital Physican. 2004; 47-52

9.       Fass R, Chey W.D, Zakko S.F. et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009; 29: 1261-72

10.     Sachs G, Shin J.M, Howden C.W. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther.2006; 23: 2–8

11.     Stedman C.A.M, Barclay M.L. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitor. Aliment Pharmacol Ther. 2000; 14: 963-78

12.     Keith M.O, Margret L.H. Dexlansoprazole MR in the Management of Gastroesophageal Reflux Disease. Clinical Medicine:Ther. 2009; 1: 1641-52

13.     Collin Jones D.G. The role and limitations of H2-receptor antagonists in the treatment of gastro-esophageal reflux disease. Aliment Pharmacol Ther. 1995; 9(1): 9-14

14.     Wilder-Smith C.H, Merki H.S. Tolerance during dosing with H2-receptor antagonists. An overview. Scand J Gastroenterol. 1992; 27(Suppl. 193):14–9.

15.     Lachman L, Howden C.W. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol. 2000; 95: 57–61.

16.     Fackler W.K, Ours T.M, Vaezi M.F, Richter J.E. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002; 122: 625–32.

17.     Peghini P.L, Katz P.O, Bracy N.A, Castell D.O. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998; 9: 763–67.

18.     Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. BedtimeH2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001; 15: 1351–56

19.     ‘Consumer reports Best Buy Drugs. Drugs to Treat Heartburn and Stomach Acid Reflux: The Proton Pump Inhibitors’. February 10, 2011  <http://www.>

20.     Savarino V, Mario F.D, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology and efficacy and safety. Pharmacol Res. 2008; 26: 1-19

21.     Marchetti F, Gerarduzzi T, Ventura A. Proton pump inhibitors in children: a review Digestive and Liver Disease. 2003; 35: 738–46

22.     Tauseef A, David N.R, William M, et al. Long-term Safety Concerns with Proton Pump Inhibitors The Am Journal of Med. 2009; 122(10): 897-902

23.     Claudene J.G, Beatriz K, Joseph S.R. Appropriate Proton Pump Inhibitor Use Among Older Adults: A Retrospective Chart Review. Am J Geriatr Pharmacother. 2008; 6: 249-54

24.     Ali RA, Egan LJ. Gastroesophageal reflux disease in pregnancy. Best Pract Res Clin Gastroenterol. 2007; 21(5): 793–806

25.     Miner P, Katz O.P, Chen Y. et al. Gastric acid control with Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole and Rabeprazole: A five way crossover study. Am J Gastroenterol. 2003; 98: 2616-20

26.     Scarpignato C. New drugs to suppress acid secretion: current and future developments. Drug Disc today:Ther strat. 2007; 4(3): 155-63

27.     Santarus, Inc. Data on file 2004.

28.     Small R. Advances in Proton Pump Inhibitor Therapy: An Immediate-Release Formulation of Omeprazole. Pharmacy and Therapeutics. 2005; 30(12): 698-715

29.     Wittbrodt E, Baum C, Peura D. Delayed release dexlansoprazole in treatment of GERD and erosive esophagitis. Clin Exp Gastroenterol. 2009; 2: 117-28

30.     Dexilant product monograph

31.     Morelli G, Chen H, Rossiter G. et al. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. Aliment Pharmacol Ther. 2011; 33(7) : 845-54

32.     Hunt R.H, Armstrong D, Yaghoobi M. et al. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther. 2008; 28: 187-99

33.     Zang W, Wu J, Atkinson S. Pharmacokinetics, pharmacodynamics and safety evaluation of a single and multiple 60 mg, 90 mg and 120 mg oral doses of modified release TAK-390 {TAK-390MR} and 30 mg oral doses of lansoprazole in healthy subjects. Gantroenterology. 2007; 132: A-487

34.     Vakily M, Zhang W, Wu J, Atkinson S. et al. Pharmacokinetics and pharmacodynamics of a known active PPI with novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009; 25: 627-38



Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available